Poor
Not Aligned
Patient Risk:
Low
Summary
The claims provided are not present in the FDA-approved label and are not supported by the prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Paxil, the brand name for the selective serotonin reuptake inhibitor paroxetine, was first brought to market by Eli Lilly & Co. in the early 1990s.
Not present in FDA-approved prescribing information.
The company secured the brand name and first‑market rights through a patent on the drug’s formulation and usage.
Not present in FDA-approved prescribing information.
Eli Lilly continues to own and market the Paxil brand in the United States and many other countries.
Not present in FDA-approved prescribing information.
The company holds the trademark.
Not present in FDA-approved prescribing information.
The company continues to produce the medication under the brand name for prescription use.
Not present in FDA-approved prescribing information.
Sales have declined since the introduction of generics.
Not present in FDA-approved prescribing information.
After the expiration of the original patents, several generic manufacturers began offering paroxetine under its chemical name.
Not present in FDA-approved prescribing information.
The generics are sold under various brand names such as PAXIL‑S, Paxil‑Free, and simply “paroxetine” in many markets.
Not present in FDA-approved prescribing information.
The generics are typically cheaper and are interchangeable with the brand-name product when prescribed by a clinician.
Not present in FDA-approved prescribing information.
Multiple pharmaceutical companies produce generic paroxetine, including Teva, Mylan, and Sandoz.
Not present in FDA-approved prescribing information.
These firms supply the generic drug to pharmacies worldwide, and their products must meet the same safety and efficacy standards set by regulatory agencies.
Not present in FDA-approved prescribing information.
Because the generic market is competitive, prices can vary between manufacturers and regions.
Not present in FDA-approved prescribing information.
The original patents covering Paxil’s formulation and therapeutic claims have long expired, allowing generic entry.
Not present in FDA-approved prescribing information.
Eli Lilly still protects certain secondary patents related to specific delivery systems or new indications, but these do not prevent the sale of generic paroxetine.
Not present in FDA-approved prescribing information.
As of the latest available data, there are no remaining active patents that block generic manufacturers from producing paroxetine in the U.S. or Europe.
Not present in FDA-approved prescribing information.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation concerns non-label information (branding/patent status) rather than patient safety data.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about brand ownership, patents, and generics are not on-label and not supported by the provided FDA label.
Suggested Improvement
Exclude non-label history and patent information when evaluating or citing prescribing-label content; restrict to on-label indications, dosing, safety, and administration.